Evaluation of Providing Coffee to Patients Postoperatively to Decrease Length of Stay in the PACU

Sponsor
TriHealth Inc. (Other)
Overall Status
Recruiting
CT.gov ID
NCT03712891
Collaborator
(none)
300
1
2
63.2
4.7

Study Details

Study Description

Brief Summary

The purpose of the study is to determine if providing coffee to patients who self-identify as coffee drinkers postoperatively will decrease the length of stay in the post-anesthesia care unit (PACU).

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Coffee
N/A

Detailed Description

Decreasing the length of stay in PACU for surgical patient is a pertinent outcome. The shorter length of stay can achieve higher patient engagement scores, while simultaneously increasing the productivity of the unit. This is achieved by making more beds available for new patients coming from the operating room (OR). One thought was that coffee would benefit the investigator's patients experience through a number of pathways. Initially, the stimulant effect of coffee would create a more alert patient. A more alert patient is more likely to comprehend home care instruction and be ready for discharge earlier. Coffee is often used as a remedy for morning sickness. Ideally the act of drinking coffee or even smelling the coffee may decrease the occurrence of Post-Operative Nausea and Vomiting (PONV) in investigator's patient population. Finally, patients frequently state that the inability to drink their morning coffee is often more difficult than not being able to eat prior to surgery. By allowing those to drink coffee in PACU this would make the patient feel that they are being cared for on an emotional level, in addition to a physical level.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Evaluation of Providing Coffee to Patients Postoperatively to Decrease Length of Stay in the PACU
Actual Study Start Date :
Oct 25, 2018
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Feb 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients receiving coffee postoperatively

Patients who self-identify as coffee drinkers and receive coffee postoperatively

Dietary Supplement: Coffee
Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)

No Intervention: Patients not receiving coffee postoperatively

Patients who self-identify as coffee drinkers and do not receive coffee postoperatively

Outcome Measures

Primary Outcome Measures

  1. PACU length of stay [6 hours]

    Post-anesthesia Care Unit length of stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  1. 18 years old or older

  2. Admitted to Bethesda North Minimally Invasive Surgery Center

  3. Reports to consume at least one cup of coffee a day for at least 5 days in a week

Exclusion Criteria

  1. History of PONV

  2. Pre-existing cardiac arrhythmias

  3. History of seizure disorder

  4. Pregnant

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bethesda North Hospital Cincinnati Ohio United States 45242

Sponsors and Collaborators

  • TriHealth Inc.

Investigators

  • Principal Investigator: Brandon Ballhaus, BSN, RN, TriHealth Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rachel Baker, Nurse Researcher, TriHealth Inc.
ClinicalTrials.gov Identifier:
NCT03712891
Other Study ID Numbers:
  • 18-050
First Posted:
Oct 19, 2018
Last Update Posted:
Aug 19, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Rachel Baker, Nurse Researcher, TriHealth Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 19, 2022